OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

OBB RSS Feed

  •  

Event Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended for other attorneys. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-2014

« Federal Circuit Authorizes Narrowing Reissue Patents That Only Add Dependent Claims | Main | McAndrews, Held & Malloy and Volker Vossius to Co-Host Patent Law Symposia in Chicago and Munich »

April 20, 2011

Comments

Vishal

The decision could go either way, and I expect a 10% stock price movement in case of Ranbaxy either way . In such a case it would be wise to buy a straddle on Ranbaxy. The stock has underperformed the indian pharmaceutical peers, due to concerns over Lipitor exclusivity forfeiture.

The comments to this entry are closed.